Alan Cherrington, PhD

Turner Chair in Diabetes Research, Professor of Molecular Biophysics at Vanderbilt University

  • Chairman of Scientific Advisory Board, Biocon, past Chairman of Amylin's Scientific Advisory Board
  • Past president of the American Diabetes Association

John Amatruda, MD

John was formerly the SVP and Franchise Head of Diabetes and Obesity at Merck Research Laboratories. He is board-certified in internal medicine, endocrinology and metabolism and has a proven track record in academics and pharmaceutical discovery research and development, including several novel candidate compounds, INDs, translational studies, development programs, and four NDAs.  John has over 15 years of experience in academic medicine, and 17 years within the medical industry. He has an extensive history as a Principal Investigator for NIH-funded basic and clinical research. Dr. Amatruda received his B.A. from Yale, his M.D. from the Medical College of Wisconsin, and completed his internship and residency in internal medicine and a fellowship in endocrinology/metabolism at The Johns Hopkins Hospital.

Marcus Hompesch, M.D.

Marcus is Founder, President and CEO of Profil Institute for Clinical Research in San Diego.  Over the past decade, Profil has been involved with almost every clinically promising drug and device development in diabetes (175+ trials).  Dr. Hompesch is an expert in the field of metabolic diseases, a licensed physician, and an entrepreneur. He spent 8 years as a practicing physician and has been involved in designing, performing and publishing many clinical studies in metabolic diseases—particularly early-phase diabetes studies. He received his M.D. from the U. of DĂĽsseldorf, Germany.  Dr. Hompesch was the founder of Med.IQ, a company that developed electronic patient records and disease-management tools for patients with diabetes, which he led as CEO until a successful exit event in 2000.

Orville G. Kolterman, M.D.

During his 20 year tenure at Amylin, Orville Kolterman, M.D. was instrumental in the development of first-in-class diabetes medicines, including SYMLIN and BYETTA injections.  Prior to his appointment as Senior Vice President & Chief Medical Officer, Dr. Kolterman held leadership roles in the regulatory, research, development, clinical and medical affairs departments, many of which were officer-level positions.  Before Amylin, he was Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the University of California Medical Center. Dr. Kolterman has served as a board member for the American Diabetes Association (ADA) Research Foundation and is a past President of the California Affiliate of the ADA.  He has held the role of Adjunct Professor of Medicine at the University of California, San Diego for over 20 years. Dr. Kolterman earned his medical degree from Stanford University School of Medicine.

Alan J. Lewis, PhD

Alan is CEO of Medistem, which is developing adult stem cell-based therapeutics.  He was previously Chairman and CEO of Ambit BioSciences, President and CEO of the Juvenile Diabetes Research Foundation, and CEO of Novocell. He served as CEO of Signal Pharma, which was acquired by Celgene.  He then was VP of Research at Wyeth-Ayerst, where he led research efforts in diabetes, cardiovascular, and other diseases. He serves as a Director of BioMarin Pharma and BIOCOM. He holds a Ph.D. in pharmacology from the U. of Wales and completed postdoctoral training at Yale University.

Sensulin News